Larkin J, Chiarion-Sileni V, Gonzalez R et al (2015) Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med 373:23–34. https://doi.org/10.1056/nejmoa1504030

Article  PubMed  PubMed Central  Google Scholar 

Romanski NA, Holmstroem RB, Ellebaek E, Svane IM (2020) Characterization of risk factors and efficacy of medical management of immune-related hepatotoxicity in real-world patients with metastatic melanoma treated with immune checkpoint inhibitors. Eur J Cancer 130:211–218. https://doi.org/10.1016/j.ejca.2020.02.041

Article  CAS  PubMed  Google Scholar 

Wang DY, Salem JE, Cohen JV et al (2018) Fatal toxic effects associated with immune checkpoint inhibitors: a systematic review and meta-analysis. JAMA Oncol 4:1721–1728. https://doi.org/10.1001/jamaoncol.2018.3923

Article  PubMed  PubMed Central  Google Scholar 

Schneider BJ, Naidoo J, Santomasso BD et al (2021) Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: ASCO Guideline Update. J Clin Oncol 39:4073–4126. https://doi.org/10.1200/jco.21.01440

Article  CAS  PubMed  Google Scholar 

Haanen J, Obeid M, Spain L et al (2022) Management of toxicities from immunotherapy: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol 33:1217–1238. https://doi.org/10.1016/j.annonc.2022.10.001

Article  CAS  PubMed  Google Scholar 

NCCN Clinical Practice Guidelines in Oncology (2023) Management of immunotherapy-related toxicities, version 2. 2023. https://www.nccn.org/professionals/physician_gls/pdf/immunotherapy.pdf. Accessed 1 August 2023

Food and Drug Administration. Prescribing Information: CELLCEPT® (mycophenolate mofetil). https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/050722s050,050723s050,050758s048,050759s055lbl.pdf. Accessed 1 August 2023

European Medicines Agency. Product information: CellCept® (mycophenolate mofetil). https://www.ema.europa.eu/en/documents/product-information/cellcept-epar-product-information_en.pdf. Accessed 1 August 2023

Bergan S, Brunet M, Hesselink DA et al (2021) Personalized therapy for mycophenolate: consensus report by the international association of therapeutic drug monitoring and clinical toxicology. Ther Drug Monit 43:150–200. https://doi.org/10.1097/ftd.0000000000000871

Article  CAS  PubMed  Google Scholar 

van Hest RM, Mathot RA, Pescovitz MD, Gordon R, Mamelok RD, van Gelder T (2006) Explaining variability in mycophenolic acid exposure to optimize mycophenolate mofetil dosing: a population pharmacokinetic meta-analysis of mycophenolic acid in renal transplant recipients. J Am Soc Nephrol 17:871–880. https://doi.org/10.1681/asn.2005101070

Article  PubMed  Google Scholar 

Staatz CE, Tett SE (2007) Clinical pharmacokinetics and pharmacodynamics of mycophenolate in solid organ transplant recipients. Clin Pharmacokinet 46:13–58. https://doi.org/10.2165/00003088-200746010-00002

Article  CAS  PubMed  Google Scholar 

Fernández A, Martins J, Villlafruela JJ et al (2007) Variability of mycophenolate mofetil trough levels in stable kidney transplant patients. Transplant Proc 39:2185–2186. https://doi.org/10.1016/j.transproceed.2007.06.025

Article  CAS  PubMed  Google Scholar 

Miura M, Satoh S, Niioka T et al (2008) Limited sampling strategy for simultaneous estimation of the area under the concentration-time curve of tacrolimus and mycophenolic acid in adult renal transplant recipients. Ther Drug Monit 30:52–59. https://doi.org/10.1097/ftd.0b013e31815f5416

Article  CAS  PubMed  Google Scholar 

Kagaya H, Niioka T, Saito M et al (2017) Effect of hepatic drug transporter polymorphisms on the pharmacokinetics of mycophenolic acid in patients with severe renal dysfunction before renal transplantation. Xenobiotica 47:916–922. https://doi.org/10.1080/00498254.2016.1235742

Article  CAS  PubMed  Google Scholar 

Ramos-Casals M, Brahmer JR, Callahan MK et al (2020) Immune-related adverse events of checkpoint inhibitors. Nat Rev Dis Primers 6:38. https://doi.org/10.1038/s41572-020-0160-6

Article  PubMed  PubMed Central  Google Scholar 

Mack CL, Adams D, Assis DN et al (2020) Diagnosis and management of autoimmune hepatitis in adults and children: practice guidance and guidelines from the American Association for the study of liver diseases. Hepatology. 72:671–722. https://doi.org/10.1002/hep.31065

Article  PubMed  Google Scholar 

van Gelder T, Tedesco Silva H, de Fijter JW et al (2010) Renal transplant patients at high risk of acute rejection benefit from adequate exposure to mycophenolic acid. Transplantation 89:595–599. https://doi.org/10.1097/tp.0b013e3181ca7d84

Article  PubMed  Google Scholar 

Meziyerh S, van Gelder T, Kers J et al (2023) Tacrolimus and mycophenolic acid exposure are associated with biopsy-proven acute rejection: a study to provide evidence for longer-term target ranges. Clin Pharmacol Ther 114:192–200. https://doi.org/10.1002/cpt.2915

Article  CAS  PubMed  Google Scholar 

Prémaud A, Rousseau A, Picard N, Marquet P (2006) Determination of mycophenolic acid plasma levels in renal transplant recipients co-administered sirolimus: comparison of an enzyme multiplied immunoassay technique (EMIT) and liquid chromatography-tandem mass spectrometry. Ther Drug Monit 28:274–277. https://doi.org/10.1097/01.ftd.0000197092.84935.ef

Article  CAS  PubMed  Google Scholar 

Kadokawa Y, Inoue S, Tatsumi A et al (2023) Efficacy and safety of mycophenolate mofetil in treating immune-related hepatitis induced by immune checkpoint inhibitor use: a retrospective study. JGH Open 7:87–97. https://doi.org/10.1002/jgh3.12868

Article  PubMed  PubMed Central  Google Scholar 

Langman LJ, LeGatt DF, Halloran PF, Yatscoff RW (1996) Pharmacodynamic assessment of mycophenolic acid-induced immunosuppression in renal transplant recipients. Transplantation 62:666–72. https://doi.org/10.1097/00007890-199609150-00022

Article  CAS  PubMed  Google Scholar 

Shah NJ, Cook MR, Wu T et al (2022) The risk of opportunistic infections and the role of antibiotic prophylaxis in patients on checkpoint inhibitors requiring steroids. J Natl Compr Canc Netw 20:800–807. https://doi.org/10.6004/jnccn.2022.7020

Article  CAS  PubMed  Google Scholar 

Kuypers DR, de Jonge H, Naesens M et al (2008) Current target ranges of mycophenolic acid exposure and drug-related adverse events: a 5-year, open-label, prospective, clinical follow-up study in renal allograft recipients. Clin Ther 30:673–683. https://doi.org/10.1016/j.clinthera.2008.04.014

Article  CAS  PubMed  Google Scholar